The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies

Anji Xiong1,2†, Deng Liu†, Huini Chen†, Guancui Yang1, Chen Xiong1, Yu Shuai1, Linqian He1, Zepeng Guo1, Liangwen Zhang1, Yuan Yang3, Beibei Cui4 and Shiquan Shuai1,2

1Department of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China, 2Inflammation and Immunology Key Laboratory of Nanchong, Nanchong, China, 3Department of Rheumatology and Immunology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China, 4Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China

Background: Although infliximab has been recommended for the second-line treatment of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis, the issue of its systemic efficacy and safety in a broader diversity of refractory noninfectious uveitis is debatable. To assess the short-term and relatively long-term efficacy of infliximab in refractory noninfectious uveitis, we performed a systematic review and meta-analysis of observational studies.

Methods: PubMed, Cochrane Library, EMBASE, and Wanfang Med Online were systematically searched from January 2005 to March 2020. Two investigators independently assessed eligibility. Data were independently collected by two investigators. The pooled proportions were estimated with patients for intraocular inflammation control and improvement of visual acuity. Pooled proportions with 95% credible intervals were computed. Study homogeneity was investigated using $I^2$ statistics to quantify the percentage of variation across studies. To pool the results, the Mantel–Haenszel fixed-effects or random-effects models were used.

Results: Of 2316 studies identified, 16 unique studies with 509 unique participants were included in the meta-analysis. The pooled proportions of intraocular inflammation control reached 92% (95% CI: 87%–98%; $I^2$: 1%; $p=0.42$) and 95% (95% CI: 93%–97%; $I^2$: 0%; $p=0.91$) in groups of ≤6- and ≥12-month follow-up durations. During the relatively long follow-up period, the pooled proportions of maintaining visual acuity stable or increasing at least one line reached 99% (95% CI: 96%–100%; $I^2$: 0%; $p=0.54$) in the involved eyes. The corticosteroid-sparing effect of infliximab was also well demonstrated, with the proportion of corticosteroid-sparing success reaching 85.5% (112/131). Besides, about serious adverse events, 2.6% (13/500) of patients experienced hypersensitivity reactions, 2.4% (12/500) of patients experienced serious infections, 1.8% (9/500) of patients experienced autoimmune diseases, and 0.6% (3/500) of patients experienced neoplasia.
INTRODUCTION

Noninfectious uveitis is a group of various etiologies-related sight-threatening inflammatory diseases which affects the iris, ciliary body, vitreous, retina, and choroid. Noninfectious uveitis is an inflammatory disease of the anterior uvea (iris and ciliary body), vitreous, retina, and choroid (Nussenblatt, 1990; Duica et al., 2018; Krishna et al., 2017; Trivedi and Katelaris, 2019). It has been estimated as the third leading cause of blindness in the world (Lee, 2015; de Parisot et al., 2017), responsible for 5–10% of visual impairment globally (Miserocchi et al., 2013; Tsirouki et al., 2018). Conversely, up to 35% of patients with uveitis suffer from significant visual loss to legal blindness (Munoz-Fernandez et al., 2006; de Smet et al., 2011). To limit potentially sight-threatening complications, good control of the inflammation in the acute phase is necessary (Toguri et al., 2018; Wildner and Diedrichs-Mohring, 2019). Currently, corticosteroids have been the mainstay of therapy for noninfectious ocular inflammatory disease (LeHoang, 2012; Rossi et al., 2019; Ormaechea et al., 2019; Jabs et al., 2000). However, in cases of refractory uveitis, corticosteroids therapy still has certain limitations (Riancho-Zarabaita et al., 2015; Duica, 2018; Koronis et al., 2019). Notably, corticosteroids alone are not sufficient for the treatment of many cases of chronic uveitis and do not prevent further relapses (Kruh and Foster, 2012; Jabs, 2018). Additionally, long-term administration of corticosteroid may result in unacceptable side effects including Cushingoid changes, iatrogenic diabetes, osteoporosis, cataract formation, increased intraocular pressure (IOP), and hormone-related glaucoma (Levy-Clarke et al., 2014; Rice et al., 2017; Oray et al., 2016). To prevent irreversible structural damage and blindness, other forms of immunosuppressive therapy are warranted (Tomkins-Netzer et al., 2012; Pasadhika and Rosenbaum, 2014). Infliximab (IFX) is a monoclonal chimeric IgG1 antibody designed to intercept and neutralize tumor necrosis factor-alpha, a key inflammatory cytokine (Lichtenstein et al., 2015; Radner and Aletaha, 2015; Horiiuchi et al., 2010). Recently, emerging evidences have shown that IFX is moderately or highly efficacious in suppressing uveitis, allowing a significant reduction in the mean corticosteroid dose (Petiti Martin et al., 2012). But, until now, IFX has been recommended as the second-line immunomodulatory agent in treating seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis (Levy-Clarke et al., 2014; Angeles-Han et al., 2019; Hatemi et al., 2019). In fact, besides them, many other diseases also can be the etiologies of noninfectious uveitis (Rosenbaum and Dick, 2018), such as birdshot retinochoroidopathy, sarcoidosis, Vogt–Koyanagi–Harada syndrome, Behcet’s disease, juvenile-onset rheumatological disease, rheumatoid arthritis, relapsing polychondritis, Crohn’s disease, psoriasis, and mucous membrane pemphigoid. Besides, there is a kind of noninfectious uveitis with no obvious underlying etiology, that is, idiopathic uveitis. Therefore, the efficacy of IFX in a broader diversity of refractory noninfectious uveitis also deserves our attention.

At present, IFX has already been recommended for the second-line treatment of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis (Levy-Clarke, 2014; Angeles-Han et al., 2019; Hatemi et al., 2019). Nevertheless, the clinical evidence or expert recommendation for IFX in a broader diversity of refractory noninfectious uveitis such as birdshot retinochoroidopathy, sarcoidosis- or rheumatoid arthritis-related uveitis, and idiopathic uveitis is still lacking.

We herein performed a meta-analysis and review aimed at systematically synthesizing the previous clinical evidence and evaluating the efficacy and safety of IFX in the treatment of a broader diversity of refractory noninfectious uveitis.

METHODS

Eligibility Criteria

The following criteria were used in the selection of studies for review: 1) noninfectious autoimmune uveitis-related studies (separate studies of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis were excluded to avoid potential bias); 2) the uveitis inflammatory activity grading defined based on the Standardization of Uveitis Nomenclature (SUN) working-group criteria (Jabs et al., 2005); 3) patients with refractory uveitis which was considered persistently active for at least 3 months despite previous systemic steroids and/or immunosuppressive treatment; 4) the follow-up duration was at least 3 months; and 5) studies with at least five patients to avoid a positive report bias.

Outcome Measures

1) Control of intraocular inflammation was defined by the anterior chamber cells and/or vitreous haze decreasing by two levels or to grade 0.5 + or 0, according to the SUN criteria and National Eye Institute system criteria adopted by SUN in at least one eye;

2) controlled visual acuity (VA), according to the SUN criteria (Jabs et al., 2005), was defined as a doubling of the visual angle (converted into a logMAR format) in the involved eye from the baseline (corresponding to an increase of three lines on a decimal scale with a logarithmic chart). In addition, we also collected information of VA maintaining stable or improving at least one line.

Conclusions: This meta-analysis provided evidence that infliximab might be a promising choice in controlling inflammatory activity, gaining visual acuity, and sparing corticosteroid use with relatively few side effects when applied in treating refractory noninfectious uveitis.

Systematic Review Registration: [website], identifier [registration number]

Keywords: infliximab, noninfectious uveitis, anti-TNF-α, uveitis treatment, refractory
3) corticosteroid-sparing success was defined as an inactive inflammation after tapering corticosteroid (topical, periorcular, oral, or intravenous) to 10 mg daily or less;

4) treatment failure was defined as the SUN-cell-activity score (anterior chamber cell/vitreous haze grade) had worsened (a two-grade increase) or had not decreased to ≤0.5 +; and

5) safety was mainly assessed by the occurrence of serious adverse events (SAEs), which included autoimmune diseases, neoplasia, hypersensitivity reactions, and serious infections. SAEs were specified as IFX treatment interruption due to unacceptable side effects. In addition, we also analyzed the incidence of common minor adverse events (MAEs).

**Sources and Search Methods**

The literature search for review was conducted using the electronic databases of published studies (i.e., PubMed, Cochrane Library, EMBASE, and Wanfang Med Online) from January 2005 to March 2020, with language restriction of only articles in English. Search algorithms included the following MESH terms: (“Infliximab” or “Tumor Necrosis Factor-alpha” or “Tumor Necrosis Factor alpha” or “Cachectin” or “Cachectin-Tumor Necrosis Factor” or “Cachectin Tumor Necrosis Factor” or “Tumor Necrosis Factor Ligand Superfamily Member 2” or “Tumor Necrosis Factor” or “TNF Superfamily, Member 2” or “TNFalpaha” or “TNF-alpha”) and (“Uveitis” or “Uveitides”). No restrictions were made on uveitis such as using the words “chronic,” “anterior,” “posterior,” “infectious,” “noninfectious,” and “autoimmune” to expand the number of hits in the literature to be screened. Uncontrolled case series, nonrandomized, retrospective clinical studies, and prospective open-label trials were included to provide evidences related to the effectiveness of IFX in uveitis ultimately, as there are no randomized controlled trials on the treatment of noninfectious uveitis with IFX up to now.

**Study Selection and Data Collection**

Three reviewers (Deng Liu, Anji Xiong, and Huini Chen) independently screened the titles and abstracts of the searched studies and determined their relevance to this meta-analysis. Full-text articles were retrieved and assessed for eligibility. Evaluations of methodological quality and risk of bias were undertaken. Any disagreements were resolved through discussion until a
consensus was reached. Key information gathered from the selected articles was listed in a standard form containing relevant details: study design type, number of patients, age and gender statistics, follow-up duration, and definitions of outcomes and results. If the same registered trial appeared on sequential or multiple publications, the data from the most recent or comprehensive publication were included. A flow diagram (Figure 1) was used to illustrate the details of the selection process including reasons for the exclusion of articles.

Quality Assessment
The methodological quality of the studies included was assessed using an 11-item checklist which was recommended by Agency for Healthcare Research and Quality (AHRQ). An item would be scored “0” if it was answered “NO” or “UNCLEAR”; if it was answered “YES,” then the item scored “1.” Article quality was assessed as follows: low quality = 0–3, moderate quality = 4–7, and high quality = 8–11. The risk of bias was assessed independently using the AHRQ risk-of-bias tool. Each of the eleven items was classified as having low, medium, or high risk of bias. Low quality is considered as high risk; moderate quality is considered as medium risk; and high quality is considered as low risk.

Data Synthesis and Analysis
Description of outcomes was graded dichotomously as “yes” or “no” responses. Studies reported their outcomes by diverse analytical methods, either based on time points (e.g., 6, or 12 months) or based on the median follow-up durations, with different analytical methods. For the analysis of the pooled proportion of controlled intraocular inflammatory activity, extracted data were categorized into two groups of “6 months or less” and “12 months or more” and this grouping helped explain the strength of evidence and relatively long-term efficacy of IFX on uveitis, respectively. The strength of evidence of nonrandomized clinical trials was rated using a scale from the Oxford Centre for Evidence-Based Medicine. All assessments were independently done by three investigators (Deng Liu, Anji Xiong, and Huini Chen).

This meta-analysis was conducted in concordance with the MOOSE guidelines for systematic reviews and meta-analyses (Stroup et al., 2000). The pooled proportions and 95% CIs were realized by the “Metaprop” program package in R 3.6.3. Study homogeneity was investigated using $I^2$ statistics to quantify the percentage of variation across studies. A random-effects model (DerSimonian–Laird method) was employed when the $I^2 > 50\%$ and $p < 0.1$; otherwise, a fixed-effects model (Mantel–Haenszel method) was used. Subgroup analysis was conducted if obvious heterogeneity existed. The difference in groups of pooled proportions was statistically significant when $p < 0.05$. A meta-analysis of clinical trials was done with a similar statistical procedure, if possible; otherwise, a systematic review was conducted. Potential publication bias was assessed by Egger’s test and presented in funnel plots. When a few studies are included in the analysis, the power of the tests is too low; therefore, publication bias was only examined if more than 10 study comparisons were included in the analysis.

RESULTS

Selection of Studies
A systematic search of multiple electronic databases yielded a total of 2,316 possible relevant articles; of these, 2,255 were excluded after scanning the titles and abstracts. After full-text scrutiny of the remaining 61 articles, 31 articles were excluded due to unmet inclusion criteria. Thereafter, 14 potentially eligible articles were removed because their data type could not be synthesized together. Finally, 16 studies were retained for the meta-analysis. A flow diagram (Figure 1) was used to illustrate the details of the selection process including reasons for the exclusion of articles.

Characteristics of Included Studies
The characteristics of the selected studies are summarized in Supplementary Table S1. Sharma et al., 2007; Sobrin et al., 2007; Simonini et al., 2008; Tugal-Tutkun et al., 2008; Giardina et al., 2011; Simonini et al., 2011; Martel et al., 2012; Pichaporn et al., 2013; Kruh et al., 2014; Lian et al., 2015; Vallet et al., 2015; Vallet et al., 2016; Mercier et al., 2018; Noy et al., 2019; Sharma et al., 2019; Yalcindag and Kose, 2020). All of these studies were observational, nonrandomized case series and had a median or mean follow-up duration of more than 6 months. In all studies, 5–10 mg/kg of infliximab was infused at weeks 0, 2, and 6 and then every 4–8 weeks. The infusion frequency and dose were depending on the indication for therapy and disease activity. One study had 3a evidence strength, three studies had 2b evidence strength, and the other twelve studies had four evidence strength according to the Oxford Centre for Evidence-Based Medicine (March 2009).

Risk-of-Bias Assessment
All of the selected articles were assessed for methodological quality. The results of the quality assessment are shown in Supplementary Table S2. One study was of high quality and fourteen studies were of moderate quality. There was one article with low quality rating. The risk for bias for the included studies is presented in Figure 2.

Control of Intraocular Inflammation
A total of 16 studies showed controlled intraocular inflammation matching our criteria, of which two (Sharma et al., 2007; Lian et al., 2015) only contained information of follow-up time $\leq$6 months; nine (Sobrin et al., 2007; Giardina et al., 2011; Simonini et al., 2011; Kruh et al., 2014; Vallet et al., 2015; Vallet et al., 2016; Noy et al., 2019; Sharma et al., 2019; Yalçindag and Kose, 2020) studies only contained information of follow-up time $\geq$12 months; and five (Simonini et al., 2008; Tugal-Tutkun et al., 2008; Martel et al., 2012; Pichaporn et al., 2013; Mercier et al., 2018) contained both. Figure 3 shows the pooled proportion results of controlled intraocular inflammation in a meta-analysis. When the follow-up duration was $\leq$6 months, the pooled controlled intraocular inflammation proportion was 92% (95% CI: 87%–98%; $p = 0.42$), with no statistically significant difference compared to a follow-up duration of $\geq$12 months (95%, 95% CI: 93%–97%; $p = 0.91$). As shown in Figure 4, with obvious heterogeneity in the
A combination of proportions with follow-up ≥ 12 months ($I^2 = 44\%$, $p < 0.01$), a subgroup analysis was conducted by dividing studies into “almost used” (≥75% of the patients used systemic CS) and “partly used” (<75% of the patients used systemic CS) according to systemic corticosteroid usage during IFX therapy. When systemic CS was used as “almost used,” the pooled proportion of intraocular inflammation control reached the highest value (96%, 95% CI: 94%–99%; $p = 0.91$). Heterogeneity was well resolved after subgroup analysis.

**Visual Acuity**
A total of nine studies (Sharma et al, 2007; Sobrin et al, 2007; Simonini et al, 2008; Giardina et al, 2011; Simonini et al, 2011; Vallet et al, 2016; Noy et al, 2019; Sharma et al, 2019; Yalçindag and Köse, 2020) reported VA outcomes. One study (Pichaporn et al, 2013) only contained information of visual acuity change based on per affected eye, two studies (Giardina et al, 2011; Lian et al, 2015) only contained information of visual acuity change based on per patient, and five studies (Sharma et al, 2007; Sobrin et al, 2007; Simonini et al, 2008; Tugal-Tutkun et al, 2008; Simonini et al, 2011) contained both. Figure 5 shows the pooled proportion results of visual acuity improvement with a long-term follow-up (≥12 months) in a meta-analysis. As shown in Figures 5, the pooled proportion of controlled VA reached 43% (95% CI: 19%–67%; $p < 0.01$) in the involved eyes (Sobrin et al, 2007; Simonini et al, 2008; Tugal-Tutkun et al, 2008; Simonini et al, 2011), and the pooled proportion of VA remaining stable or improving at least one line reached 99%.
(95% CI: 96%–100%; p = 0.54) in the involved eyes Figure 6 (Sobrin et al, 2007; Simonini et al, 2008; Tugal-Tutkun et al, 2008; Giardina et al, 2011). In addition, in one study (Yalçindag and Köse, 2020), a total of 20 patients reported a significant improvement of BCVA (best-corrected visual acuity) after 1 year of IFX treatment when compared with pretreatment.

**Corticosteroid-Sparing**

Information on corticosteroid-sparing was extractable in eight of the sixteen studies. 82.9% (68/82) of patients completely discontinued corticosteroids. Additionally, 85.5% (112/131) of patients achieved corticosteroid-sparing success. Details are recorded in Supplementary Table S1.

**Safety**

Fifteen studies (Sharma et al, 2007; Sobrin et al, 2007; Simonini et al, 2008; Tugal-Tutkun et al, 2008; Giardina et al, 2011; Simonini et al, 2011; Martel et al, 2012; Pichaporn et al, 2013; Kruh et al, 2014; Vallet et al, 2015; Vallet et al, 2016; Mercier et al, 2018; Noy et al, 2019; Sharma et al, 2019; Yalçindag and Köse, 2020).
provided information on serious adverse events (SAEs). 2.6% (13/500) of patients experienced hypersensitivity reactions, 2.4% (12/500) of patients experienced serious infections, 1.8% (9/500) of patients experienced autoimmune diseases, and 0.6% (3/500) of patients experienced neoplasia. In addition, 11.2% (54/481) of patients reported minor adverse events (MAEs) in fourteen studies (Sharma et al, 2007; Sobrin et al, 2007; Simonini et al, 2008; Tugal-Tutkun et al, 2008; Simonini et al, 2011; Martel et al, 2012; Pichaporn et al, 2013; Kruh et al, 2014; Vallet et al, 2015; Vallet et al, 2016; Mercier et al, 2018; Noy et al, 2019; Sharma et al, 2019; Yalçindag and Köse, 2020). The most frequently reported MAEs were minor infections (2.9%, 14/481), skin rash (1.9%, 9/481), fatigue (1.5%, 7/481), and injection-site reactions (1.0%, 5/481). Details are recorded in Supplementary Table S1.

Treatment Interruption
A total of 14 studies (Sharma et al, 2007; Sobrin et al, 2007; Simonini et al, 2008; Tugal-Tutkun et al, 2008; Simonini et al, 2011; Martel et al, 2012; Pichaporn et al, 2013; Kruh et al, 2014; Vallet et al, 2015; Vallet et al, 2016; Mercier et al, 2018; Noy et al, 2019; Sharma et al, 2019; Yalçindag and Köse, 2020) had the information of IFX discontinuation. Details are also recorded in Supplementary Table S1. 13.7% (55/402) of patients discontinued IFX treatment, of which 8.2% (33/402) of patients discontinued IFX for SAEs, and 5.5% (22/402) of patients discontinued IFX for other reasons.

Publication Bias
Funnel plot results for potential publication bias are shown in Supplementary Figure S1. From visual inspection of the funnel plot, there was pronounced asymmetry denoting publication bias. The Egger test for funnel plot asymmetry was significant in the proportion of intraocular inflammation control in long term (≥12 months) (p = 0.009). Other outcome indicators were observed for less than ten studies, so publication bias was not examined.

2020) provided information on serious adverse events (SAEs). 2.6% (13/500) of patients experienced hypersensitivity reactions, 2.4% (12/500) of patients experienced serious infections, 1.8% (9/500) of patients experienced autoimmune diseases, and 0.6% (3/500) of patients experienced neoplasia. In addition, 11.2% (54/481) of patients reported minor adverse events (MAEs) in fourteen studies (Sharma et al, 2007; Sobrin et al, 2007; Simonini et al, 2008; Tugal-Tutkun et al, 2008; Simonini et al, 2011; Martel et al, 2012; Pichaporn et al, 2013; Kruh et al, 2014; Vallet et al, 2015; Vallet et al, 2016; Mercier et al, 2018; Noy et al, 2019; Sharma et al, 2019; Yalçindag and Köse, 2020). The most frequently reported MAEs were minor infections (2.9%, 14/481), skin rash (1.9%, 9/481), fatigue (1.5%, 7/481), and injection-site reactions (1.0%, 5/481). Details are recorded in Supplementary Table S1.

DISCUSSION
We systematically reviewed many aspects of the efficacy of IFX in refractory noninfectious uveitis including control of intraocular inflammation, improvement of visual acuity, and corticosteroid-sparing. In addition, we assessed safety by the occurrence of serious adverse events (SAEs) which included autoimmune diseases, neoplasia, hypersensitivity reactions, and serious infections. We defined the controlled intraocular inflammation by the anterior chamber cells and/or vitreous haze decreasing by two levels or to grade 0.5 + or 0, according to the SUN criteria and National Eye Institute system criteria adopted by SUN in at least one eye. Perhaps the pooled proportion of controlled intraocular inflammation based on each eye can better explain the curative effect of IFX on affected eyes, but in fact, detailed information about inflammation control of affected eyes is lacking and unavailable in most studies. Considering the diversity of etiologies of uveitis included, the etiologies of patients and the corresponding number were documented in detail in Supplementary Table S1. We calculated the percentage of patients with seronegative spondyloarthropathy- or juvenile idiopathic arthritis. According to rough calculation, the patients with seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis accounted for about 1/5. Therefore, uveitis related to these etiologies has a limited impact on statistical results. The efficacy of IFX in the treatment of a broader diversity of refractory noninfectious uveitis is still well proved.

First of all, we divided the endpoint into two subgroups to examine the short-term (≤6 months) and relatively long-term (≥12 months) effects on inflammation control. In our combined analysis of short-term and relatively long-term follow-up periods, we found the pooled proportions of intraocular inflammation control reached 92% (95% CI: 87%–98%) and 95% (95% CI: 93%–97%), respectively, indicating that stable therapeutic effect can be obtained. We found obvious heterogeneity in the combination of proportions with follow-up ≥12 months (I² =
44%, \( p < 0.01 \)), and thus, a subgroup analysis was conducted according to the patient proportion of using systemic corticosteroids during IFX treatment. After the subgroup analysis, heterogeneity was well resolved. Therefore, the subgroup analysis indicated the “almost used” of CS contributed to such heterogeneity exited. When the subgroup was “almost used,” the pooled proportion of activity control reached 96% (95% CI: 94%–99%; \( p = 0.91 \)) which was better than the “partly used” (81%, 95% CI: 75%–88%; \( p = 0.51 \)).

Comparing the results of these two subgroups can help us to judge that IFX combined with CS may have a better therapeutic effect and can control inflammation more quickly. Therefore, in order to gain a better long-term efficacy (≥12 months) on inflammation control, early combined application of IFX and CS may be worth recommending.

In the short-term follow-up group (≤6 months), we did not conduct a subgroup analysis according to the patient proportion of using systemic corticosteroids because almost no heterogeneity was observed, and more importantly, the information on CS use ratio in short-term follow-up was also lacking and unextractable. Thus, we cannot explain whether it will be a better short-term efficacy in intraocular inflammation control when choosing an early combination therapy of IFX and CS in noninfectious uveitis. However, we still strongly recommend the early combination of IFX and CS in uveitis in order to obtain a better long-term curative effect and prevent progressive irreversible damage to the eyes.

We analyzed the results of visual acuity change based on the affected eye. According to the meta-analyses, respectively, the pooled proportion of controlled VA based on the affected eye is 43% (95% CI: 19%–67%). But this result existed obvious heterogeneity. The main reason may be that in some involved eyes, the structural damage was already present before IFX therapy, which caused VA that can only be maintained in a stable state instead of increasing further. Therefore, we analyzed the pooled proportion of maintaining VA stable or increasing at least one line. According to the outcomes of meta-analysis, the pooled proportion of maintaining stable VA or increasing at least one line based on the affected eye was 99% (95% CI: 96%–100%; \( p = 0.54 \)) with no heterogeneity observed (\( I^2 = 0\)), which indicates a significant effect of IFX in maintaining VA stability and even improving. Although there is a limited reference value for the pooled proportion of controlled VA due to its significant heterogeneity, the good efficacy of IFX in maintaining VA stability and even improving is still well proved in this meta-analysis.

We briefly analyzed the corticosteroid-sparing effect. According to the extractable information, in eight studies, 82.9% (68/82) of patients completely discontinued corticosteroid and 85.5% (112/131) of patients achieved corticosteroid-sparing success. We did not conduct meta-analysis for the corticosteroid-sparing effect because the number of studies which can extract corticosteroid-sparing information is too few. Besides, some studies which take corticosteroid discontinuation as the success criterion of corticosteroid-sparing have not included patients who still maintain low-dose corticosteroid (≤10 mg/ day). Although the corticosteroid-sparing effect was simply analyzed by averages without considering the weight of each study, the outcomes also indicated that IFX may have a good corticosteroid-sparing effect. In addition, such a significant corticosteroid-sparing effect also avoided adverse events induced by corticosteroids during uveitis activity control. According to the simple analysis of the incidence of side effects, some serious adverse events such as autoimmune diseases, neoplasia, hypersensitivity reactions, and serious infections also should be noted when using IFX to treat noninfectious uveitis, although they have only a low incidence.

Above all, several promising results have contributed to the reasonable use of IFX in the clinical treatment of refractory uveitis. 1) IFX may have a stable inflammation control effect in the short-term and relatively long-term treatment of uveitis. 2) An early combination of IFX and systemic CS can obtain better long-term efficacy in inflammation control of uveitis. 3) IFX can effectively control the worsening of VA. 4) IFX has a good corticosteroid-sparing effect. 5) IFX was generally well tolerated in the treatment of most noninfectious uveitis. On the rate of intraocular inflammation control, one multicenter study (Vallet, 2015) yielded similar results in the response rates to infliximab in uveitis, which were 87 and 93% at 6 and 12 months. Comparatively, our study contained data from more studies, larger sample size (426 vs. 77), wider range of age, and broader diversity of noninfectious uveitis and, therefore, might have a better population representation.

**Limitations**

This study has some limitations. First, the included studies had various uveitis etiologies such as JIA, Behcet’s disease, sarcoidosis, and spondyloarthropathy-associated uveitis. Owing to the limited number of studies and paucity of clinical data, we did not conduct subgroup analysis according to basic disease, although clinical physicians might be interested in IFX efficacy for uveitis of different etiologies. Second, it could cause bias when the study included refractory noninfectious uveitis related to seronegative spondyloarthropathy or juvenile idiopathic arthritis. Limited by the included studies, we did not have access to individual patient data with refractory noninfectious uveitis related to seronegative spondyloarthropathy or JIA, so we could not eliminate these patients. Third, the proportion of corticosteroid-sparing, IFX discontinuation, and observed AEs were simply analyzed by averages without considering the weight of each study. Finally, in view of the fact that most studies used for analysis only had evidence strengths of Oxford Centre for Evidence-Based Medicine 2b, 3a, and 4, a dialectic point of view is still needed when referring to these results.

**CONCLUSION**

This meta-analysis revealed the overall efficacy of IFX in the treatment of refractory noninfectious uveitis and demonstrated its good effects in short-term and long-term intraocular inflammation control, VA improvement, and corticosteroid-sparing. Meanwhile, we presented the common adverse events in the uveitis treatment with IFX, which may provide a reference for future prevention of adverse events. More high-quality, large-scale clinical trials with a similar design are needed to further
prove the efficacy of IFX in the treatment of uveitis with stronger evidence.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS
AX conceived this project; DL, AX, and HC designed the study; GY and CX searched the literature data; YS and LH extracted the data; DL, AX, CX, GY, ZG, LZ, YY, BC, and SS drafted the manuscript; all authors critically reviewed the manuscript and approved the final version of the manuscript. DL, AX and HC have equally contributed as first authors to this manuscript.

FUNDING
This work was supported by the Government and School Cooperation Program of Nanchong, Sichuan, China 19SXHZ0148.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.620340/full#supplementary-material

REFERENCES
Ángeles-Han, S. T., Ringold, S., Beukelman, T., Lovell, D., Cuello, C. A., Becker, M. L., et al. (2019). 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 71, 864–877. doi:10.1002/acr.2387110.2019.04885
de Parisot, A., Kodykjian, L., Errera, M.-H., Sedira, N., Heron, E., Pérard, L., et al. (2017). Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). Am. J. Ophthalmol. 178, 176–185. doi:10.1016/j.ajo.2017.03.029
de Smet, M. D., Taylor, S. R. J., Bodaghi, B., Misericocchi, E., Murray, P. I., Pleyer, U., et al. (2011). Understanding Uveitis: The Impact of Research on Visual Outcomes. Prog. Retin. Eye Res. 30, 452–470. doi:10.1016/j.preteyeres.2011.06.005
Duca, L., Voinea, L.-M., Mitulescu, C., Istrate, S., Coman, I.-C., and Ciuluvica, R. (2018). The Use of Biologic Therapies in Uveitis. rjo 61, 105–113. doi:10.22336/rjo.2018.16
Giardina, A., Ferrante, A., Ciccia, F., Vadala, M., Giardina, E., and Triolo, G. (2011). One Year Study of Efficacy and Safety of Infliximab in the Treatment of Patients with Ocular and Neurological Behçet’s Disease Refractory to Standard Immunosuppressive Drugs. Rheumatol. Int. 31, 33–37. doi:10.1007/s00296-009-1213-z
Hatemi, G., Seyahi, E., Fresko, I., Hatemi, G., Talarico, R., and Seyahi, E. (2019). One Year in 2019: Behçet’s Syndrome. Clin. Exp. Rheumatol. 37 Suppl 121 (Suppl 121), 3–17.
Horiuuchi, T., Mitoma, H., Harashima, S.-l., Tsukamoto, H., and Shimoda, T. (2010). Transmembrane TNF-α: Structure, Function and Interaction with Anti-TNF Agents. Rheumatology 49, 1215–1228. doi:10.1093/rheumatology/keq031
Jabs, D. A., Nussenblatt, R. B., and Rosenbaum, J. T. (2005). Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am. J. Ophthalmol. 140, 509–516. doi:10.1016/j.ajo.2005.03.057
Jabs, D. A. (2018). Immunosuppression for the Uveitides. Ophthalmology 125, 193–202. doi:10.1016/j.ophtha.2017.08.007
Jabs, D. A., Rosenbaum, J. T., Foster, C. S., Holland, G. N., Jaffe, G. J., and Jabs, D. A., et al. (2000). Guidelines for the Use of Immunosuppressive Drugs in Patients with Ocular Inflammatory Disorders: Recommendations of an Expert Panel. Am. J. Ophthalmol. 130, 492–513. doi:10.1016/s0002-9394(00)00659-0
Koronis, S., Stavrakas, P., Balidis, M., Kozeis, N., and Tranos, P. G. (2019). Update on Treatment of Uveitic Macular Edema. Ddt 13, 667–680. doi:10.2147/ddt.s166092
Krishna, U., Ajanaku, D., Denniston, A. K., and Gkika, T. (2017). Uveitis: a Sight-Threatening Disease Which Can Impact All Systems. Postgrad. Med. J. 93, 766–773. doi:10.1136/postgradmedj-2017-134891

Kruh, J., and Foster, C. S. (2012). The Philosophy of Treatment of Uveitis: Past, Present and Future. Dev. Ocular. Immunol. 51, 1–6. doi:10.1159/000336183
Kruh, J. N., Yang, P., Suelves, A. M., and Foster, C. S. (2014). Infliximab for the Treatment of Refractory Noninfectious Uveitis. Ophthalmol. 121, 358–364. doi:10.1016/j.ophtha.2013.07.019
Lee, D. (2015). Intraocular Implants for the Treatment of Autoimmune Uveitis. J. Ocul. Immunol. Inflamm. 6, 650–666. doi:10.3390/jobi6030650
LeHoang, P. (2012). The Gold Standard of Noninfectious Uveitis: Corticosteroids. Dev. Ophthalmol. 51, 7–28. doi:10.1159/000336676
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., and Van Gelder, R. N. (2014). Expert Panel Recommendations for the Use of Anti-tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology 121, 785–796. e783. doi:10.1016/j.ophtha.2013.09.048
Lian, F., Zhou, J., Wei, C., Wang, Y., Xu, H., Liang, L., et al. (2015). Anti-TNF Agents and Methotrexate in Spondyloarthritis Related Uveitis in a Chinese Population. Clin. Rheumatol. 34, 1913–1920. doi:10.1007/s10067-015-2989-8
Lichtenstein, L., Ron, Y., Kivity, S., Ben-Horin, S., Israeli, E., Fraser, G. M., et al. (2015). Infliximab-Related Infusion Reactions: Systematic Review. Ecoocc 9, 806–815. doi:10.1093/ecoocc/jov096
Martel, J. N., Esterberg, E., Naggal, A., and Acharya, N. R. (2012). Infliximab and Adalimumab for Uveitis. Ocul. Immunol. Inflamm. 20, 18–26. doi:10.3109/09273948.2011.633205
Mercier, A.-E., Ribeiro, E., Korobelnik, J.-F., Delyfer, M.-N., and Rouger, M.-B. (2018). Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients. Ocul. Immunol. Inflamm. 26, 477–484. doi:10.1080/09273948.2016.1236968
Misericocchi, E., Fogliato, G., Modorati, G., and Bandello, F. (2013). Review on the Worldwide Epidemiology of Uveitis. Eur. J. Ophthalmol. 23, 705–717. doi:10.5056/ejo.5000278
Muñoz-Fernández, S., and Martín-Mola, E. (2006). Uveitis. Best Pract. Res. Clin. Rheumatol. 20, 487–505. doi:10.1016/j.bpr.2006.03.008
Noy, A., Ujwala, S. S., Ashley, A., Cristiano, R., and Jennifer, H. C. (2019). Successful Treatment with Infliximab after Adalimumab Failure in Pediatric Noninfectious Uveitis. J. AAPOS 3, 151. doi:10.1016/j.aaapos.2019.02.006
Nussenblatt, R. B. (1990). The Natural History of Uveitis. Int. Ophthalmol. 14, 303–308. doi:10.1023/b:iooph.1990.01.63549
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., and Foster, C. S. (2016). Long-term Side Effects of Glucocorticoids. Expert Opin. Drug Saf. 15, 457–465. doi:10.1517/14740338.2016.1140743
Ormachea, M. S., Hassan, M., Onghanseng, N., Park, J. H., Mahajan, S., and Kirwi, K. Y., et al. (2019). Safety of Systemic Therapy for Noninfectious Uveitis. Expert Opin. Drug Saf. 18, 1219–1235. doi:10.1080/14740338.2019.1692810
Pasadhika, S., and Rosenbaum, J. T. (2014). Update on the Use of Systemic Biologic Agents in the Treatment of Noninfectious Uveitis. Biologics 8, 67–81. doi:10.2147/bt.541477
Petrou, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Petiti Martin, G., Sana, S. S., and Stephen, C. F. (2013). Inflammamix Treatment of Patients with Birdshot Retinochoroidopathy. *Ophthalmology* 3, 588–592. doi:10.1016/j.jophtha.2012.05.048

Radner, H., and Aletaha, D. (2015). Anti-TNF in Rheumatoid Arthritis: an Overview. *Wiener Med. Wochenschr* 165, 3–9. doi:10.1007/s10354-015-0344-y

Riancho-Zarrabeitia, L., Calvo-Río, V., Blanco, R., Mesquida, M., Adan, A. M., Herreras, J. M., et al. (2015). Anti-TNF-α Therapy in Rheumatoid Arthritis Associated with Sarcoidosis: Multicenter Study of 17 Patients. *Sem. Arthritis Rheum.* 45, 361–368. doi:10.1016/j.sar.2015.05.010

Rice, J. B., White, A. G., Scarpati, L. M., Wan, G., and Nelson, W. W. (2017). Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. *Clin. Ther.* 39, 2216–2229. doi:10.1016/j.clinthera.2017.09.011

Rosenbaum, J. T., and Dick, A. D. (2018). The Eyes Have It. *Arthritis Rheumatol.* 70, 1533–1543. doi:10.1002/art.40568

Rossi, D. C., Ribi, C., and Guex-Crosier, Y. (2019). Treatment of Chronic Non-infectious Uveitis and Scleritis. *Swiss Med. Wkly* 149, w20025. doi:10.4414/smw.2019.20025

Sharma, S. M., Damato, E., Hinchcliffe, A. E., Andrews, C. D., Myint, K., Lee, R., et al. (2019). Long-term Efficacy and Tolerability of TNF-alpha Inhibitors in the Treatment of Non-infectious Ocular Inflammation: an 8-year Prospective Surveillance Study. *Br. J. Ophthalmol.* doi:10.1136/bjo.2018-312767

Sharma, S. M., Ramanan, A. V., Riley, P., and Dick, A. D. (2007). Use of Infliximab in Juvenile Onset Rheumatological Disease-Associated Refractory Uveitis: Efficacy in Joint and Ocular Disease. *Ann. Rheum. Dis.* 66, 840–841. doi:10.1136/ard.2006.065441

Simonini, G., Taddio, A., Cattalini, M., Caputo, R., De Libero, C., Naviglio, S., et al. (2011). Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: an Open-Label Comparative Study of Adalimumab versus Infliximab. *Arthritis Care Res.* 63, 612–618. doi:10.1002/acr.20404

Simonini, G., Zannin, M. E., Caputo, R., Falcomini, F., de Martino, M., Zolli, F., et al. (2008). Loss of Efficacy during Long-Term Infliximab Therapy for Sight-threatening Childhood Uveitis. *Rheumatology* 47, 1510–1514. doi:10.1093/rheumatology/ken298

Sobrin, L., Kim, E. C., Christen, W., Papadaki, T., Letko, E., and Foster, C. S. (2007). Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease. *Arch. Ophthalmol.* 125, 895–900. doi:10.1001/archoph.125.7.895

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., et al. (2000). Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. *Jama* 283, 2008–2012. doi:10.1001/jama.283.15.2008

Toguri, J. T., Leishman, E., Szczesniak, A. M., Laprairie, R. B., Oehler, O., Straiker, A. J., et al. (2018). Inflammation and CB2 Signaling Drive Novel Changes in the Ocular Lipidome and Regulate Immune Cell Activity in the Eye. *Prostaglandins & Other Lipid Mediators* 139, 54–62. doi:10.1016/j.prostaglandins.2018.09.004

Tomkins-Netzer, O., Taylor, S. R. J., and Lightman, S. (2012). Corticosteroid-sparing Agents: New Treatment Options. *Dev. Ophthalmol.* 51, 47–56. doi:10.1159/000336186

Trivedi, A., and Katelaris, C. (2019). The Use of Biologic Agents in the Management of Uveitis. *Intern. Med. J.* 49, 1352–1363. doi:10.1111/imj.14215

Tsiouris, T., Dastriroud, A., Syneonidis, C., Tounakaki, O., Brazitikou, I., Kalogeropoulos, C., et al. (2018). A Focus on the Epidemiology of Uveitis. *Ocul. Immunol. Inflamm.* 26, 2–16. doi:10.1080/09273948.2016.1196713

Tugul-Tutkun, I., Ayranci, Ö., Kasapcopur, O., and Kir, N. (2008). Retrospective Analysis of Children with Uveitis Treated with Infliximab. *J. Am. Assoc. Pediatr. Ophthalmol. Strabismus* 12, 611–613. doi:10.1016/j.jaapos.2008.08.007

Vallet, H., Riviére, S., Sanna, A., Deroux, A., Moulis, G., Addimamada, O., et al. (2015). Efficacy of Anti-TNF Alpha in Severe And/or Refractory Behçet’s Disease: Multicenter Study of 124 Patients. *J. Autoimmun.* 62, 67–74. doi:10.1016/j.jaut.2015.06.005

Vallet, H., Seve, P., Biard, L., Baptiste Fraisou, J., Bielefeld, P., Perard, L., et al. (2016). Infliximab versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study from the French Uveitis Network. *Arthritis Rheumatol.* 68, 1522–1530. doi:10.1002/art.39667

Wildner, G., and Diedrichs-Möhling, M. (2019). Resolution of Uveitis. *Semin. Immunopathol.* 41, 727–736. doi:10.1007/s00281-019-00758-z

Yalcindag, N., and Köse, H. C. (2020). Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon. *Ocul. Immunol. Inflamm.* 28, 305–314. doi:10.1080/09273948.2019.1606256

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Xiong, Liu, Chen, Yang, Shuai, He, Guo, Zhang, Yang, Cui and Shuai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.